ARTICLE

FORMULATION AND IN VITRO EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF VENLAFAXINE

  1. HOME
  2. ARTICLE

02 Pages : 10-24

http://dx.doi.org/10.31703/gpsr.2017(II-I).02      10.31703/gpsr.2017(II-I).02      Published : Dec 2017

Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine

Abstract

    Sustained release matrix tablets of venlafaxine were formulated using synthetic polymers (ethylcellulose & hydroxypropyl methylcellulose). Six (06) different batches of matrix tablets of venlafaxine (dose 75 mg) were prepared by the wet granulation method. Polymers were used alone or in combination. The physical properties of compressed tablets were evaluated. In vitro release drug studies were performed in phosphate buffer at pH 6.8 over 24 hours. The drug release data fitted well to the First-order (R2 = 0.9725 – 0.9900). The n value obtained for most batches ranged from 0.523 to 0.946 indicates that the drug is released through an anomalous or non–Fickian transport. Results revealed that the combination of ethyl cellulose (EC) and hydroxypropyl methylcellulose produced a sustained effect compared to hydroxypropyl methylcellulose alone. Formulation F6 containing single polymer (EC) showed the highest control over initial burst release, and extended-release of the drug continued up to 16 hours.

    Sustained Release Matrix Tablets, Venlafaxine, Ethyl Cellulose (EC), hydroxypropyl methylcellulose

    (1) Zubair Anwar
    M.Phil Scholar, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, Punjab, Pakistan.
    (2) Tanveer Ahmed Khan
    PhD Scholar, Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
    (3) Muhammad Farhan Sohail
    Associate Professor, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, Punjab, Pakistan.
    (4) Maryam Anwar
    PhD Scholar, Saulat Institute of Pharmaceutical Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Fulltext PDF

References

  • Aboelwafa, A. A., & Basalious, E. B. (2010). Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. Aaps Pharmscitech, 11(3), 1026-1037.
  • AHMED, A., ALI, S. A., HASSAN, F., ALI, S. S., & HAQUE, N. (2001). Evaluation of acetaminophen tablets by control test. Pakistan journal of pharmaceutical sciences, 14(2), 47- 55.
  • Akash, M., Khan, I., Shah, S., Asghar, S., Massud, A., Qadir, M., & Akbar, A. (2010). Sustained release hydrophilic matrices based on xanthan gum and hydroxypropyl methylcellulose: development, optimization, in vitro and in vivo evaluation. J App Pharm, 4(2), 89-103.
  • Al-Saidan, S. M., Krishnaiah, Y. S., Patro, S., & Satyanaryana, V. (2005). In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. Aaps Pharmscitech, 6(1), E14- E21.
  • Ali, L., Ahmad, M., & Usman, M. (2015). Evaluation of cross-linked hydroxypropyl methylcellulose graft-methacrylic acid copolymer as extended release oral drug carrier. Cell. Chem. Technol, 49(2), 143-151.
  • Ali, L., Ahmad, M., Usman, M., & Yousuf, M. (2014). Controlled release of highly water-soluble antidepressant from hybrid copolymer poly vinyl alcohol hydrogels. Polymer bulletin, 71(1), 31-46.
  • Ali, M., Singh, S., Kumar, A., Singh, S., Ansari, M., & Pattnaik, G. (2010). Preparation and in vitro evaluation of sustained release matrix tablets of phenytoin sodium using natural polymers. Int J Pharm Pharm Sci, 2(3), 174-179.
  • Allen, L., & Ansel, H. C. (2013). Ansel's pharmaceutical dosage forms and drug delivery systems: Lippincott Williams & Wilkins.
  • Amchin, J., Zarycranski, W., Taylor, K. P., Albano, D., & Klockowski, P. M. (1999). Effect of venlafaxine on the pharmacokinetics of risperidone. The Journal of Clinical Pharmacology, 39(3), 297-309.
  • Atul, A., & Prashant, Z. (2010). Designing and evaluation of extended release tablet of Venlafaxine hydrochloride using hydrophobic matrix. Der Pharmacia Lettre, 2(1), 329-335.
  • Avachat, A., Bornare, P., & Dash, R. (2011). Sustained release microspheres of ropinirole hydrochloride: effect of process parameters. Acta Pharmaceutica, 61(4), 363-376.
  • Bajdik, J., Pintye-Hódi, K., PlaninÅ¡ek, O., Regdon Jr, G., Srčič, S., & Erős, I. (2004). Film coating as a method to enhance the preparation of tablets from dimenhydrinate crystals. International journal of pharmaceutics, 269(2), 393-401.
  • Basak, S., Reddy, B. J., & Mani, K. L. (2006). Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet. Indian Journal of Pharmaceutical Sciences, 68(5).
  • Brahmareddy, D., Madhulatha, A., & Priyanka, R. (2011). Formulation and Evaluation of Venlafaxine HCl Sustained Release Pellets.
  • Butani, S. B. (2013). Development and Optimization of Venlafaxine Hydrochloride Sustained Release Triple Layer Tablets Adopting Quality by Design Approach. Pharmacology & Pharmacy, 4(3A), 9-16.
  • Carignatto, C. R. R., Oliveira, K. S. M., de Lima, V. M. G., & de Oliva Neto, P. (2011). New culture medium to xanthan production by Xanthomonas campestris pv. campestris. Indian journal of microbiology, 51(3), 283-288.
  • Chandrasekhar, Y., Jaganathan, K., Senthil Selvi, R., Perumal, P., & Vani, T. (2011). Formulation and Invitro evaluation of didanosine sustained release matrix tablets using natural gums. Int J Res Pharm Biomed Sci, 2(1), 245-251.
  • Chirico, S., Dalmoro, A., Lamberti, G., Russo, G., & Titomanlio, G. (2007). Analysis and modeling of swelling and erosion behavior for pure HPMC tablet. Journal of Controlled Release, 122(2), 181-188.
  • Commission, B. P. (2011). British Pharmacopoeia 2009. Journal of Research and Education in Indian Medicine (Estt. 1982), 17(1), 64-64.
  • Conaghey, O., Corish, J., & Corrigan, O. (1998). Iontophoretically assisted in vitro membrane transport of nicotine from a hydrogel containing ion exchange resins. International journal of pharmaceutics, 170(2), 225-237.
  • Crowley, M. M., Schroeder, B., Fredersdorf, A., Obara, S., Talarico, M., Kucera, S., & McGinity, J. W. (2004). Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion. International journal of pharmaceutics, 269(2), 509-522.
  • Dahmen, N., Marx, J., Hopf, H. C., Tettenborn, B., & Röder, R. (1999). Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke, 30(3), 691- 692.
  • Dastidar, S. G., Ganguly, K., Chaudhuri, K., & Chakrabarty, A. (2000). The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. International journal of antimicrobial agents, 14(3), 249-251.
  • Dineshmohan, S., Gupta, V., Ramesh, A., Harika, V., & Sravani, T. (2015). Effect of HPMC and ethyl cellulose polymeric granules and its combinations.
  • Durand, J., Deplanque, G., Montheil, V., Gornet, J., Scotte, F., Mir, O., . . . Mitry, E. (2011). Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 23(1), 200-205.
  • Ford, J. L., Rubinstein, M. H., & Hogan, J. E. (1985). Formulation of sustained release promethazine hydrochloride tablets using hydroxypropyl- methylcellulose matrices. International journal of pharmaceutics, 24(2-3), 327-338.
  • Fukuda, M., Peppas, N. A., & McGinity, J. W. (2006). Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. International journal of pharmaceutics, 310(1-2), 90-100.
  • Gohel, M., Soni, C., Nagori, S., & Sarvaiya, K. (2008). Modulation of venlafaxine hydrochloride release from press coated matrix tablet. Indian Journal of Pharmaceutical Sciences, 70(3), 292.
  • Gupta, S., Singh, R. P., Sharma, R., Kalyanwat, R., & Lokwani, P. (2011). Osmotic pumps: A review. International journal of comprehensive pharmacy, 2(6), 1-8.
  • Hadi, M. A., Babu, V. L., & Pal, N. (2012). Formulation and evaluation of sustained releasematrix tablets of glimepiride based on combinationof hydrophilic and hydrophobic polymers.
  • Hanekamp, B., Zijlstra, J., Tulleken, J., Ligtenberg, J., Van Der Werf, T., & Hofstra, L. (2005). Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report. Neth J Med, 63(8), 316-318.
  • Hannan, N., Hamzah, Z., Akinpeloye, H. O., & Meagher, D. (2007). Venlafaxine - mirtazapine combination in the treatment of persistent depressive illness. Journal of Psychopharmacology, 21(2), 161-164.
  • Higuchi, T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of pharmaceutical sciences, 52(12), 1145-1149.
  • Howell, C., Wilson, A. D., & Waring, W. (2007). Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. British journal of clinical pharmacology, 64(2), 192-197.
  • Ilett, K. F., Kristensen, J. H., Hackett, L. P., Paech, M., Kohan, R., & Rampono, J. (2002). Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. British journal of clinical pharmacology, 53(1), 17-22.
  • Jain, A., Chauhan, R., Singh, S., Kulkarni, S., & Jain, S. (2015). OPTIMIZATION OF COATING MATERIAL FOR SUSTAINED RELEASE VENLAFAXINE HYDROCHLORIDE TABLET. INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH, 5(3), P1-P12.
  • Jain, N. K. (1997). Controlled and novel drug delivery: CBS publishers & distributors.
  • Jain, S., Yadav, S., & Patil, U. (2008). Preparation and evaluation of sustained release matrix tablet of furosemide using natural polymers. Research journal of pharmacy and technology, 1(4), 374- 376.
  • Kamboj, S., Gupta, G., & Oberoy, J. (2009). Matrix tablets: An important tool for oral controlled- release dosage forms. Pharmainfo. net, 7(6).
  • Kar, R., Mohapatra, S., & Barik, B. (2009). Design and characterization of controlled release matrix tablets of Zidovudine. Asian J Pharm Cli Res, 2(2), 54-61.
  • Kasper, S., Herman, B., Nivoli, G., Van Ameringen, M., Petralia, A., Mandel, F. S., . . . Bandelow, B. (2009). Efficacy of pregabalin and venlafaxine- XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International clinical psychopharmacology, 24(2), 87-96.
  • Katzman, M. A., & Jacobs, L. (2007). Venlafaxine in the treatment of panic disorder. Neuropsychiatric disease and treatment, 3(1), 59.
  • Keny, R., Mankame, S., & Lourenco, C. (2009). Formulation and evaluation of once daily minocycline hydrochloride extended release matrix tablets. Indian Journal of Pharmaceutical Sciences, 71(3), 295.
  • Kumar, G., Gauri, S., Hooda, A., Saini, S., & Garg, A. (2011). Fabrication and evaluation of flavoured mucoadhesive buccal tablet of caffeine as CNS stimulant. Int. J. Universal Pharm. Life Sci, 1(2), 85-97.
  • Lachman, L., Lieberman, H. A., & Kanig, J. L. (1976). The theory and practice of industrial pharmacy: Lea & Febiger Philadelphia.
  • Lee, H., Kim, J. H., Min, B.-H., Lee, J. H., Son, H. J., Kim, J. J., . . . Rhee, P.-L. (2010). Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. The American journal of gastroenterology, 105(7), 1504.
  • Lieberman, H. A., & Lachman, L. (1980). Pharmaceutical Dosage Forms: Tablets: 1980 (Vol. 1): Marcel Dekker.
  • Maderich, A. B., & Sugita, E. T. (1996). Absorption enhancement of dextran sulfate after enteral administration in a dispersion. International journal of pharmaceutics, 137(1), 85-94.
  • Malipeddi, V. R., Awasthi, R., & Dua, K. (2016). Formulation and evaluation of controlled release ethylcellulose and polyethylene glycol microspheres containing metoprolol tartrate. Interventional Medicine and Applied Science, 8(2), 60-67.
  • Mamidala, R. K., Ramana, V., Sandeep, G., Lingam, M., Gannu, R., & Yamsani, M. R. (2009). Factors influencing the design and performance of oral sustained/controlled release dosage forms. Int. J. Pharm. Sci. and Nanotech, 2(3), 583-594.
  • Mehta, P., Deshmukh, G. J., Seth, A., & Banty, P. (2011). Formulation and evaluation of sustained release matrix tablets of captopril. Indo American Journal of Pharmaceutical Research, 1(6), 69-83.
  • Moin, A., & Shivakumar, H. (2010). Formulation of sustained-release diltiazem matrix tablets using hydrophilic gum blends. Tropical Journal of Pharmaceutical Research, 9(3).
  • Moosavi-Nasab, M., Pashangeh, S., & Rafsanjani, M. (2010). Effect of fermentation time on xanthan gum production from sugar beet molasses. World Academy of Science, Engineering and Technology, 4, 1018-1021.
  • Mughal, M. A., Iqbal, Z., & Neau, S. H. (2011). Guar gum, xanthan gum, and HPMC can define release mechanisms and sustain release of propranolol hydrochloride. Aaps Pharmscitech, 12(1), 77-87.
  • NAKABAYASHI, K., SHIMAMOTO, T., & MIMA, H. (1980). Stability of packaged solid dosage forms. I. Shelf-life prediction for packaged tablets liable to moisture damage. Chemical and Pharmaceutical Bulletin, 28(4), 1090-1098.
  • Nokhodchi, A., Raja, S., Patel, P., & Asare-Addo, K. (2012). The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts: BI, 2(4), 175.
  • Patel, J., & Shah, N. Formulation and Evaluation of Sustained Release Tablets Containing Atomoxetine Hydrochloride.
  • Patil, S., Kulkarni, U., & Bhavik, P. (2010). Formulation and evaluation of diclofenac potassium matrix tablets. International Journal of Pharmaceutical Sciences and Research, 1(8), 88-92.
  • Peppas, N. A., & Sahlin, J. J. (1989). A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. International journal of pharmaceutics, 57(2), 169-172.
  • PINEDA, E. A. G., & Hechenleitner, A. (2004). Characterization of ethylcellulose films containing natural polysaccharides by thermal analysis and FTIR spectroscopy. Acta Farm. Bonaerense, 23(1), 53-57.
  • Prescott, J. K., & HOOSFELD, R. (1994). Maintaining product uniformity and uninterrupted flow to direct-compression tableting presses. Pharmaceutical technology, 18(6), 98-98.
  • Priya, C., & Rajkumari, K. A. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY.
  • Rajendran, N., Natarajan, R., Subhashini, R., & Patel, H. (2011). Formulation and evaluation of sustained release bilayer tablets of metformin HCl and pioglitazone HCl. Int J Curr Pharm Res, 3(3), 118-122.
  • Rajesh, K., Venkataraju, M., & Gowda, D. (2009). Effect of hydrophilic natural gums in formulation of oral-controlled release matrix tablets of propranolol hydrochloride. Pakistan journal of pharmaceutical sciences, 22(2).
  • Ranjha, N. M., Madni, A., Bakar, A. A., Talib, N., Ahmad, S., & Ahmad, H. (2014). Preparation and characterization of isosorbide mononitrate hydrogels obtained by free-radical polymerization for site-specific delivery. Tropical Journal of Pharmaceutical Research, 13(12), 1979-1985.
  • Robinson, J., & Lee, V. H. (1987). Controlled drug delivery: fundamentals and applications: CRC Press.
  • Rodríguez, H., & Aguilar, L. (1997). Detection of Xanthomonas campestris mutants with increased xanthan production. Journal of Industrial Microbiology and Biotechnology, 18(4), 232-234.
  • Salger, S. V., Danki, L. S., Hiremath, S., & Sayeed, A. (2010). Preparation and evaluation of sustained release matrix tablets of propranolol hydrochloride. International journal of pharma and bio sciences, 1(4), 227-241.
  • Salsa, T., Veiga, F., & Pina, M. (1997). Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Development and Industrial Pharmacy, 23(9), 929-938.
  • Senthilnathan, B., & Rupenagunta, A. (2011). Formulation development and evaluation of venlafaxine hydrochloride orodispersible tablets. International Journal of Pharmaceutical Sciences and Research, 2(4), 913.
  • Shah, S. N. H., Asghar, S., Choudhry, M. A., Akash, M. S. H., Rehman, N. u., & Baksh, S. (2009). Formulation and evaluation of natural gum- based sustained release matrix tablets of flurbiprofen using response surface methodology. Drug Development and Industrial Pharmacy, 35(12), 1470-1478.
  • Shaikh, A., Shaikh, P., Pawar, Y., Kumbhar, S., & Katedeshmukh, R. (2011). Effect of gums and excipients on drug release of ambroxol-HCl sustained release matrices. J Curr Pharm Res, 6(1), 11-15.
  • Shanmugarathinam, A., & Puratchikody, A. (2014). Formulation and Characterization of Ritonavir loaded Ethylcellulose Buoyant Microspheres. Journal of Pharmaceutical Sciences and Research, 6(8), 274-277.
  • Siepmann, J., & Peppas, N. (2001). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced drug delivery reviews, 48(2-3), 139- 157.
  • Singhvi, G., & Singh, M. (2011). In-vitro drug release characterization models. International Journal of Pharmacutical Studies and Research, 2, 77- 84.
  • Urbán-Morlán, Z., Mendoza-Elvira, S. E., Hernández- Cerón, R. S., Alcalá-Alcalá, S., Ramírez- Mendoza, H., Ciprián-Carrasco, A., . . . Quintanar-Guerrero, D. (2015). Preparation of ethyl cellulose nanoparticles by solvent- displacement using the conventional method and a recirculation system. Journal of the Mexican Chemical Society, 59(3), 173-180
  • Varshosaz, J., Tavakoli, N., & Kheirolahi, F. (2006). Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. Aaps Pharmscitech, 7(1), E168- E174.
  • Verma, N. K., Alam, G., Mishra, J., Vishwakarma, D., & Singh, V. K. Formulation development and characterization of ethyl cellulose microspheres of ibuprofen.

Cite this article

APA

    APA : Anwar, Z., Khan, T. A., & Sohail, M. F. (2017). Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine. Global Pharmaceutical Sciences Review, II(I), 10-24. https://doi.org/10.31703/gpsr.2017(II-I).02

CHICAGO

    CHICAGO : Anwar, Zubair, Tanveer Ahmed Khan, and Muhammad Farhan Sohail. 2017. "Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine." Global Pharmaceutical Sciences Review, II (I): 10-24 doi: 10.31703/gpsr.2017(II-I).02

HARVARD

    HARVARD : ANWAR, Z., KHAN, T. A. & SOHAIL, M. F. 2017. Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine. Global Pharmaceutical Sciences Review, II, 10-24.

MHRA

    MHRA : Anwar, Zubair, Tanveer Ahmed Khan, and Muhammad Farhan Sohail. 2017. "Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine." Global Pharmaceutical Sciences Review, II: 10-24

MLA

    MLA : Anwar, Zubair, Tanveer Ahmed Khan, and Muhammad Farhan Sohail. "Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine." Global Pharmaceutical Sciences Review, II.I (2017): 10-24 Print.

OXFORD

    OXFORD : Anwar, Zubair, Khan, Tanveer Ahmed, and Sohail, Muhammad Farhan (2017), "Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine", Global Pharmaceutical Sciences Review, II (I), 10-24

TURABIAN

    TURABIAN : Anwar, Zubair, Tanveer Ahmed Khan, and Muhammad Farhan Sohail. "Formulation and In Vitro Evaluation of Sustained Release Matrix Tablets of Venlafaxine." Global Pharmaceutical Sciences Review II, no. I (2017): 10-24. https://doi.org/10.31703/gpsr.2017(II-I).02